東陽光(600673.SH):擬以宜昌東陽光藥業股權置換宜昌藥研所持等價的廣藥股權
格隆匯4月13日丨東陽光(600673.SH)公佈,經公司與控股股東協商一致,擬以控股股東之控股子公司宜昌東陽光藥研發有限公司(簡稱“宜昌藥研”)所持的等價值的廣藥股權置換公司持有的宜昌東陽光藥業的股權。經評估,公司擬置出的宜昌東陽光藥業5328.00萬股股份(簡稱“置出標的”)評估價值為7.767億元,對應的等價值的廣藥的註冊資本為1169.86萬元(簡稱“置入標的”)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.